Philip Morris International heads into its October 21 earnings print with a striking shift in options sentiment — call buyers have taken control for the first time in months, even as the stock dips slightly on the week.
The clearest signal this week is in options. The put/call ratio has fallen to 1.01, nearly three standard deviations below its 20-day average of 1.17 — the most call-skewed reading of the past year, against a 52-week low of 0.71 and a high of 1.24. For a stock that has been running with heavy put coverage throughout August and into early September, this reversal is sharp. The PCR was as high as 1.24 on September 8. It has compressed by almost a fifth in two weeks. That kind of move points to traders rotating into call exposure, building upside optionality ahead of the Q3 release rather than defending against a drawdown.
Short interest tells a quiet story and does nothing to complicate the options picture. Bears hold just 1.1% of the free float — a low absolute level — and that position has been trimmed 3.9% over the past week. The lending market confirms there is no squeeze pressure: borrow availability is effectively unlimited, with more than 1.1 billion shares available in the lending pool. Cost to borrow is a negligible 0.45%, easing roughly 4% on the week. The ORTEX short score of 31.9 is consistent with a name where short sellers have little conviction and even less urgency. None of this creates the conditions for a forced unwind; shorts here are ambient rather than aggressive.
The Street is broadly constructive, though with one important caveat at the top of the target range. UBS lifted its target to $193 from $182 this week — the most recent move — while keeping a Neutral rating, suggesting even the sceptics see the stock as fairly priced rather than overvalued at $190.23. After Q2 earnings in July, Citi, Barclays, Morgan Stanley, Stifel, and Needham all raised targets in a cluster, with the bullish camp landing between $205 and $225. The consensus mean target is $208, implying roughly 9% upside from current levels. The bull case rests on smoke-free products — IQOS and Zyn — continuing to take volume share, with organic revenue growth potentially reaccelerating in 2027. Bears point to combustible volume declines running near 3%, Japan excise risk on IQOS, and ZYN destocking in the US as near-term margin headwinds. The PE multiple has eased slightly to 21.2x, drifting down 0.3 turns over the past 30 days. EV/EBITDA is running at 16.8x, also drifting marginally lower. Neither reads as a crowded valuation for a consumer staples compounder with strong free cash flow.
Ownership is concentrated and incrementally positive. Capital Research and Management — the largest holder at 18.8% of shares — added 3.6 million shares in the most recent filing period. Vanguard, BlackRock, and State Street all increased positions, with FMR adding 2.8 million shares. No activist filing is on the 13D register. All 13D/G disclosures on file are passive 13G positions — stakes as last disclosed, with holders capable of falling below 5% without a further filing. The insider data is stale at 140 days old, so no current read-through from that channel; the most recent filed transactions were director stock grants in May, which carry minimal signalling value.
PM's last two earnings prints produced positive reactions: up 1.6% the day after Q2 and 0.97% after Q1, with the five-day windows showing considerably more follow-through — gains of 5.5% and 10.9% respectively. The pattern suggests the market has been rewarding the beat-and-raise cadence rather than just the headline number. Peers were mixed on the week: MO fell 1.7%, BATS dropped 1.4%, and IMB slid 2.7%, while PM held to a 2% decline before Tuesday's bounce. Japan Tobacco was the outlier, gaining 1.6% — a split that reflects differing smoke-free exposure across the group.
The next pivot point is the October 21 print, where the debate will focus less on whether PM is growing and more on whether IQOS volumes in Japan and ZYN trajectory in the US can absorb the headwinds that bearish analysts have been flagging since the spring.
See the live data behind this article on ORTEX.
Open PM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
